Emulating clinical trial designs with real-world data can offer valuable predictive insights. A study published in BMJ Open Diabetes Research & Care used national claims data to mirror the design of the ongoing SEPRA trial, comparing once-weekly injectable semaglutide with standard-of-care (SoC) therapies in adults with type 2 diabetes mellitus (T2DM) on metformin monotherapy.

Using the Optum Clinformatics database (2017–2022), investigators identified a 1:1 propensity score–matched cohort of 1,144 semaglutide and SoC initiators. Semaglutide initiators were 30% more likely to reach A1C <7% (risk ratio 1.30; 95% CI 1.16–1.45) and had a greater mean A1C reduction (–1.3% vs –1.1%). The findings were consistent with interim SEPRA trial results, validating the predictive potential of real-world evidence.

These results highlight how well-designed real-world studies can complement pragmatic randomized trials and strengthen evidence on therapeutic effectiveness in routine clinical practice.